1448189-55-6

Basic information

• Product Name: (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate
• Synonyms: (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate
• CAS NO: 1448189-55-6
• Molecular Weight: 344.367
• Mol File: 1448189-55-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate(1448189-55-6)
• EPA Substance Registry System: (2S,4R)-benzyl 4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxylate(1448189-55-6)

Safety Data

• Hazardous Substances Data: 1448189-55-6(Hazardous Substances Data)

Upstream product

• 62147-27-7 (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride 
• 19668-85-0 2-(3-methylisoxazol-5-yl)acetic acid 
• 1864003-48-4 (2S,4R)-benzyl 4-hydroxypyrrolidine-2-carboxylate hydrochloride 

Downstream Products

• 1448187-28-7 (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1360616-17-6 (2S,4R)-N-(4-chlorobenzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide 
• 1448186-43-3 (2S,4R)-N-(4-(1H-pyrrol-3-yl)benzyl)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)pyrrolidine-2-carboxamide 
• 1360616-29-0 (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(oxazol-5-yl)benzyl)pyrrolidine-2-carboxamide 
• 1418120-52-1 (2S,4R)-4-hydroxy-1-(2-(3-methylisoxazol-5-yl)acetyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide 

Relevant articles and documents

Is NMR fragment screening fine-tuned to assess druggability of protein-protein interactions?

Modulation of protein-protein interactions (PPIs) with small molecules has been hampered by a lack of lucid methods capable of reliably identifying high-quality hits. In fragment screening, the low ligand efficiencies associated with PPI target sites pose

COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE

The present invention relates to novel compounds which find utility as modulators, especially inhibitors of VCB E3 Ubiquitin Ligase and as bioactive agents for use as therapeutics for the stimulation of erythropoiesis in a patient or subject including inducement of EPO production in the patient or subject, for the treatment of chronic anemia and ischemia (limits brain injury during episodes of localized anemia, ischemia and/or stroke and damage to cardiovascular tissue during cardiovascular ischemia), as well as enhancing wound healing processes. Pharmaceutical compositions comprising effective amounts of compounds according to the present invention alone or in combination with an additional erythropoieses stimulating agent such as EPO under the tradename procrit or epogen or darbapoietin alfa under the tradename aranesp. Methods of stimulating erythropoiesis in a subject or patient, including increasing the number of red blood cells and/or hematocrit of the patient, treating anemia, including chronic anemia and anemia associated with chronic kidney disease, dialysis, and cancer chemotherapy, ischemia, stroke and damage to cardiovascular tissue during cardiovascular ischemia as well as enhancing wound healing processes and preventing/reducing scarring secondary to healing represent additional aspects of the present invention. Local enhancement of angiogenesis through induction of VEGF including wound healing and reduction of stent occlusion remain additional aspects of the present invention.